Candidate: Inhaled nitric oxide (iNO) for treatment of mild/moderate COVID-19
Type: Inhaled nitric oxide as a supportive measure for COVID-19 patients with associated pulmonary complications based on formulations shown to have successfully treated patients with SARS-CoV, due to its genomic similarity to SARS-CoV-2
Status: Xijing and MGH have launched two Phase II trials assessing inhaled nitric oxide in patients with mild/moderate COVID-19 (NCT04290871, withdrawn March 24; and NCT04305457, recruiting patients). A day later, the nitric oxide delivery device developer Nu-Med Plus said it was closely monitoring the trials, and had talks with the FDA about bringing its products to market more quickly. Nu-Med has also had talks with the U.S. Department of Veterans Affairs about research opportunities related to iNO technology and COVID-19.
COVID-19: 200 Candidates and Counting
To navigate through the >200 potential therapeutic and vaccine options for COVID-19, GEN has grouped the candidates into four broad categories based on their developmental and (where applicable) clinical progress:
● FRONT RUNNER – the most promising therapeutics/vaccines based on clinical progress, favorable data or both.
● DEFINITELY MAYBE – earlier phases with promising partners, or more advanced candidates in development that have generated uneven data
● KEEPING AN EYE ON… – interesting technology, attracting notable partners, or both, but preliminary data.
● TOO SOON TO TELL – longshots pending additional experimental and/or clinical data.
GEN has also tagged the most common treatment types:
● ANTIVIRAL
● VAX
● ANTIBODY
● RNA